Newsgroup: it.economia.borsa.estero
Titolo: ATIS ULTIME OCCASIONI PER COMPRARLE A PREZZI STRACCIATI

ATIS ULTIME OCCASIONI PER COMPRARLE A PREZZI STRACCIATI
Advanced Tissue Sciences (ticker: ATIS, exchange: NASDAQ) News Release -
11-Dec-2001
----------------------------------------------------------------------------
----
Dermagraft Receives Reimbursement Pass-Through Code
LA JOLLA, Calif., Dec 11, 2001 (BW HealthWire) -- Advanced Tissue Sciences,
Inc. (NASDAQ: ATIS) and Smith & Nephew plc (NYSE: SNN) announced today that
Dermagraft(R) Human Fibroblast-Derived Skin Substitute has received an
Ambulatory Payment Classification (APC) pass-through code under the Hospital
Outpatient Prospective Payment System from the Centers for Medicare &
Medicaid Services.
The pass-through payment code for Dermagraft (C 9201) covers Medicare
patients with diabetic foot ulcers treated in a hospital outpatient setting.
It will be effective January 1, 2002. This will allow each of the Medicare
local carriers/fiscal intermediaries to begin developing coverage guidelines
to determine when, how often, and under what conditions they will pay for
this important therapy for patients with chronic diabetic foot ulcers.
The pass-through payment code is the first step toward receipt of a $5
million milestone payment from Smith & Nephew, subject to other conditions
in the agreements between the two companies.
The Food and Drug Administration cleared the Pre-market Approval Application
for Dermagraft in the treatment of chronic foot ulcers in patients with
diabetes on September 28, 2001.
    Background Information
Advanced Tissue Sciences is redefining tissue repair and transplantation
with human-based products developed and derived from its patented
tissue-engineering technology. The company's efforts are concentrated in
four therapeutic areas where the body cannot heal itself: wound care;
aesthetic and reconstructive; cardiovascular; and orthopedic. Three products
are currently on the market: Dermagraft, for the treatment of diabetic foot
ulcers; TransCyte(R), a temporary covering for second- and third-degree
burns; and NouriCel(TM) for skincare and cosmetic markets. The company's
tissue-engineered, human-based collagen is awaiting FDA approval for wrinkle
injections. Other products are in clinical or pre-clinical trials.
The company has developed strategic alliances designed to unlock longer term
product opportunities. These include two joint ventures with Smith & Nephew,
a strategic alliance with Inamed Corporation and a collaboration with
Medtronic, Inc. More information on Advanced Tissue Sciences is available at
www.advancedtissue.com
.
Smith & Nephew is a global medical device company employing about 7,000
people with operations in 34 countries and established sales in 90
countries. The company markets technically innovative products principally
in the areas of orthopedics, endoscopy and wound management to deliver
cost-effective solutions, significant physician advantages and real patient
benefits. Smith & Nephew is the leading company in the global wound
management market.
Statements in this press release that are not strictly historical may be
"forward-looking" statements, which involve risks and uncertainties. No
assurances can be given, for example, that the other conditions required for
payment of the milestone from Smith & Nephew will be met. Actual results may
differ materially from those described in this press release due to risks
and uncertainties that exist in the company's operations, including, without
limitation, uncertainties related to clinical trials, the ability to obtain
the appropriate regulatory approvals, the ability to obtain additional
milestones and financing to continue operations when needed, a history of
operating losses and accumulated deficits, market acceptance of products,
the company's reliance on collaborative relationships, the company's ability
to obtain and retain patent protection, as well as other risks detailed from
time to time in publicly available filings with the Securities and Exchange
Commission including, without limitation, Advanced Tissue Sciences' Annual
Report on Form 10-K for the year ended December 31, 2000 and the company's
quarterly reports on Form 10-Q for the quarters ended March 31, June 30 and
September 30, 2001. The company undertakes no obligation to release publicly
the results of any revision to these forward-looking statements to reflect
events or circumstances arising after the date hereof.
CONTACT:          Advanced Tissue Sciences, Inc., La Jolla
                  Abe Wischnia, 
858/713-7802
 (Investor Contact)
                  Senior Director, Investor Relations
                  or
                  Julie Reynolds, 
858/713-7802
 (Media Contact)
                  Corporate Communications Manager
URL:              
http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2001 Business Wire.  All rights reserved.

Guarda che dopo Natale iniziano i saldi.....
;-P

 ha scritto nel messaggio
news:x2qR7.3711$3r4.1...@news1.tin.it...


 tornerà la lunga estate calda da pianto...


 >SI  PER TUTTI QUELLI CHE LE HANNO VENDUTE A QUESTI PREZZI.....


 > >SI  PER TUTTI QUELLI CHE LE HANNO VENDUTE A QUESTI PREZZI.....Sei un
povero illlluso non vedi come le spingono ?


>Sei un povero illuso non vedi come le spingono ?
Chi è che le spinge?? Anzi mi sembra il contrario....

per "roberto"hai solo da venderle se non ci credi  cazzi tuoi
